GlaxoSmithKline (GB:GSK) has released an update.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
GlaxoSmithKline has expanded the approval of its RSV vaccine, Arexvy, in Japan to include adults aged 50-59 at increased risk due to certain health conditions. This marks a significant step as Japan becomes the first country to approve the vaccine for this age group, following similar approvals in 35 countries including the US. The decision is backed by a global phase III trial showing consistent safety and immunogenicity in this demographic.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.